KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2017 - 2025)

Alnylam Pharmaceuticals' Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $13.5 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 4.67% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $55.7 million, down 1.79%, while the annual FY2025 figure was $55.7 million, 1.79% down from the prior year.
  • Depreciation & Amortization (CF) reached $13.5 million in Q4 2025 per ALNY's latest filing, down from $13.8 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $15.0 million in Q2 2024 to a low of $9.5 million in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $12.9 million, with a median of $13.5 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 65.52% in 2021, then dropped 24.93% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $11.4 million in 2021, then increased by 25.81% to $14.3 million in 2022, then dropped by 5.79% to $13.5 million in 2023, then grew by 5.09% to $14.2 million in 2024, then decreased by 4.67% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Depreciation & Amortization (CF) are $13.5 million (Q4 2025), $13.8 million (Q3 2025), and $13.9 million (Q2 2025).